Infection and Chemotherapy最新文献

{"title":"Reply: Response to Possibility of Decreasing Incidence of Human Immunodeficiency Virus Infection in Korea.","authors":"Jihwan Bang","doi":"10.3947/ic.2024.0015","DOIUrl":"10.3947/ic.2024.0015","url":null,"abstract":"","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"94-95"},"PeriodicalIF":2.8,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990879/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140289564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Possibility of Decreasing Incidence of Human Immunodeficiency Virus Infection in Korea.","authors":"Sudip Bhattacharya","doi":"10.3947/ic.2024.0001","DOIUrl":"10.3947/ic.2024.0001","url":null,"abstract":"","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"92-93"},"PeriodicalIF":2.8,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990880/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140289566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"No Significant Differences in Presepsin Levels According to the Causative Microorganism of Bloodstream Infection.","authors":"Beomki Lee, Jong Eun Park, Sun Joo Yoon, Chi-Min Park, Nam Yong Lee, Tae Gun Shin, Eun-Suk Kang","doi":"10.3947/ic.2023.0066","DOIUrl":"10.3947/ic.2023.0066","url":null,"abstract":"<p><strong>Background: </strong>CD14 recognizes lipopolysaccharide (LPS), and presepsin is a fragment of soluble CD14. Still, it remains uncertain whether Gram-negative bacteria induce higher presepsin levels than other microorganisms. To address this question, this study aimed to analyze presepsin levels based on microorganisms isolated in blood cultures.</p><p><strong>Materials and methods: </strong>This study was a single-center study comprising suspected sepsis patients enrolled from July 2020 to September 2020. A total of 95 patients with a single isolate confirmed in blood culture were analyzed to evaluate if there are any differences in presepsin levels according to microbial isolates. Plasma presepsin level was measured using PATHFAST assay kit and analyzer (LSI Medience Corporation, Tokyo, Japan).</p><p><strong>Results: </strong>There were 26 Gram-positive bacteremia, 65 Gram-negative bacteremia, and 3 fungemia patients with median presepsin levels of 869, 1,439, and 11,951 pg/mL, respectively. Besides, one case of algaemia demonstrated a presepsin level of 1,231 pg/mL. Our results showed no statistically significant difference in presepsin levels among patients with Gram-positive bacteremia, Gram-negative bacteremia, and fungemia. Furthermore, presepsin levels did not differ significantly among bloodstream infections caused by bacteria that were isolated from at least three different patients. In particular, Gram-positive bacteria such as <i>Staphylococcus aureus</i> and <i>Enterococcus faecalis</i> were able to induce presepsin levels comparable to those induced by Gram-negative bacteria.</p><p><strong>Conclusion: </strong>We demonstrated that there were no significant differences in plasma presepsin levels according to microbial isolates in blood culture. The major cause of the variability in presepsin levels during bloodstream infection might be the immunogenicity of each microorganism rather than the presence of LPS in the microorganism.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"47-56"},"PeriodicalIF":4.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990877/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139099208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevention of Cytomegalovirus Infection in Solid Organ Transplant Recipients: Guidelines by the Korean Society of Infectious Diseases and the Korean Society for Transplantation.","authors":"Kyungmin Huh, Sang-Oh Lee, Jungok Kim, Su Jin Lee, Pyoeng Gyun Choe, Ji-Man Kang, Jaeseok Yang, Heungsup Sung, Si-Ho Kim, Chisook Moon, Hyeri Seok, Hye Jin Shi, Yu Mi Wi, Su Jin Jeong, Wan Beom Park, Youn Jeong Kim, Jongman Kim, Hyung Joon Ahn, Nam Joong Kim, Kyong Ran Peck, Myoung Soo Kim, Sang Il Kim","doi":"10.3947/ic.2024.0016","DOIUrl":"10.3947/ic.2024.0016","url":null,"abstract":"<p><p>Cytomegalovirus (CMV) is the most important opportunistic viral pathogen in solid organ transplant (SOT) recipients. The Korean guideline for the prevention of CMV infection in SOT recipients was developed jointly by the Korean Society for Infectious Diseases and the Korean Society of Transplantation. CMV serostatus of both donors and recipients should be screened before transplantation to best assess the risk of CMV infection after SOT. Seronegative recipients receiving organs from seropositive donors face the highest risk, followed by seropositive recipients. Either antiviral prophylaxis or preemptive therapy can be used to prevent CMV infection. While both strategies have been demonstrated to prevent CMV infection post-transplant, each has its own advantages and disadvantages. CMV serostatus, transplant organ, other risk factors, and practical issues should be considered for the selection of preventive measures. There is no universal viral load threshold to guide treatment in preemptive therapy. Each institution should define and validate its own threshold. Valganciclovir is the favored agent for both prophylaxis and preemptive therapy. The evaluation of CMV-specific cell-mediated immunity and the monitoring of viral load kinetics are gaining interest, but there was insufficient evidence to issue recommendations. Specific considerations on pediatric transplant recipients are included.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"101-121"},"PeriodicalIF":4.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140289563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Essentiality of Support Groups in Response to the HIV Epidemic in the Philippines.","authors":"Dalmacito A Cordero","doi":"10.3947/ic.2024.0008","DOIUrl":"10.3947/ic.2024.0008","url":null,"abstract":"","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"90-91"},"PeriodicalIF":4.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990878/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140289591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antimicrobial Resistance of <i>Streptococcus pneumoniae</i> Clinical Serotypes between 2017 and 2022 in Crete, Greece.","authors":"Sofia Maraki, Viktoria Eirini Mavromanolaki, Dimitra Stafylaki, Evangelia Iliaki-Giannakoudaki, Anna Kasimati, George Hamilos","doi":"10.3947/ic.2023.0098","DOIUrl":"10.3947/ic.2023.0098","url":null,"abstract":"<p><strong>Background: </strong>Pneumococcal disease is still considered a global problem. With the introduction of pneumococcal conjugate vaccines (PCVs) serotype epidemiology changed, but antimicrobial resistance persists constituting a serious problem. The current study aimed to determine the serotype distribution and the antimicrobial susceptibility of recent <i>Streptococcus pneumoniae</i> isolates, following implementation of the 13-valent conjugate vaccine (PCV13).</p><p><strong>Materials and methods: </strong>From January 2017 to December 2022 we evaluated 116 nonduplicate <i>S. pneumoniae</i> isolates collected from adult patients (21 - 98 years) cared for in the University Hospital of Heraklion, Crete, Greece. Pneumococcal isolates were serotyped by the Quellung reaction, and antimicrobial susceptibility testing was performed using E-test. Multidrug resistance (MDR) was defined as non-susceptibility to at least one agent in ≥3 classes of antibiotics.</p><p><strong>Results: </strong>Among the 116 isolates, 31% were recognized as invasive pneumococcal strains, while 69% were non-invasive. The isolates tested belonged to 25 different serotypes. The most prevalent serotypes were 11A (10.3%), and 35B (10.3%), followed by 3 (9.5%), 15A (7.8%), 25F (6.9%), 19A (5.3%), 35F (5.3%), and others (44.6%). The coverage rates of PCV13 and the pneumococcal polysaccharide vaccine (PPSV23) were 26.7% and 57.8%, respectively. PCV13 and PPSV23 serotypes decreased between 2017 - 2019 and 2020 - 2022, with a parallel increase in the non-vaccine types. Resistance rates to erythromycin, clindamycin, trimethoprim/sulfamethoxazole, penicillin, levofloxacin, and ceftriaxone, were 40.5%, 21.6%, 13.8%, 12.1%, 3.4%, and 0%, respectively. All isolates were susceptible to vancomycin, linezolid, and daptomycin. MDR was observed among 36 (31%) <i>S. pneumoniae</i> isolates.</p><p><strong>Conclusion: </strong>The increasing levels of resistance in <i>S. pneumoniae</i> in Crete, Greece, highlight the need for continuous surveillance of antimicrobial resistance and development of strategies for its reduction, including antimicrobial stewardship programs, increased pneumococcal vaccination, and development of next generation PCVs with a wider serotype coverage.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"73-82"},"PeriodicalIF":4.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990890/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139974408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to \"Adult Immunization Policy in Korea\".","authors":"Sudip Bhattacharya, Sandip Bhattacharya","doi":"10.3947/ic.2023.0108","DOIUrl":"10.3947/ic.2023.0108","url":null,"abstract":"","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"88-89"},"PeriodicalIF":4.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139099210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification and Antimicrobial Susceptibilities for Patients with Non-tuberculous Mycobacteria Infection in Jeju Island: Single-Center Retrospective Study.","authors":"Misun Kim, Sang Taek Heo, Jaechun Lee, Jong Hoo Lee, Miok Kim, Changhwan Kim, Gil Myeong Seong, Myeong Jin Kang, Jeong Rae Yoo","doi":"10.3947/ic.2023.0052","DOIUrl":"10.3947/ic.2023.0052","url":null,"abstract":"<p><strong>Background: </strong>The distribution of species and characteristics of non<bold>-</bold>tuberculous mycobacteria (NTM) differ, and surveillance data for changes in antimicrobial susceptibilities of NTM is insufficient. This study analyzed the changes in antimicrobial susceptibility trends across NTM species and assessed the appropriateness of empirical antimicrobial drugs for NTM.</p><p><strong>Materials and methods: </strong>We retrospectively analyzed the clinical characteristics, including demographics, distribution of NTM species, antimicrobial drug susceptibilities, and outcomes, at a teaching hospital in Jeju Island from 2009 - 2022.</p><p><strong>Results: </strong>Overall, 342 patients were included in the analysis; 93.0% were classified into the pulmonary group (PG) and 7.0% into the extrapulmonary group (EPG). The isolation rate of <i>Mycobacterium avium</i> was significantly higher in PG (36.8% <i>vs.</i> 0%, <i>P</i> = 0.001), while that of <i>Mycobacterium fortuitum</i> was significantly higher in EPG (4.5% <i>vs.</i> 31.3%, <i>P</i> = 0.001). The antimicrobial susceptibility rate is higher against clarithromycin (89.9%) and amikacin (83.3%) and lower against rifampin (54.7%) and ethambutol (28.1%). The susceptibility rate to clarithromycin was over 80%, but those to rifampin and ethambutol showed decreasing annual trends. Of the 162 patients who received empirical antimicrobial therapy, actual antimicrobial susceptibility rates were high (90.1%) using empirical macrolide, and relatively low using ethambutol and rifampin (28.0% and 58.8%, respectively).</p><p><strong>Conclusion: </strong>This is the first study of analysis of the distribution, baseline characteristics, and antimicrobial susceptibility of isolated NTM species in pulmonary and extrapulmonary patients in Jeju Island over 10 years. Policies that continuously monitor changes in susceptibility rate are required to ensure effective treatment strategies.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"13-24"},"PeriodicalIF":4.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990891/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10542285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Possibility of Decreasing Incidence of Human Immunodeficiency Virus Infection in Korea.","authors":"Minkyeong Lee, Wan Beom Park, Eu Suk Kim, Yeonjae Kim, Sang-Won Park, Eunyoung Lee, Myoung-Don Oh, Nam Joong Kim, Hong Bin Kim, Kyoung-Ho Song, Pyoeng Gyun Choe, Chang Kyung Kang, Chan Mi Lee, Yunsang Choi, Song Mi Moon, Seong Jin Choi, Jaehyun Jeon, Jihwan Bang","doi":"10.3947/ic.2023.0056","DOIUrl":"10.3947/ic.2023.0056","url":null,"abstract":"<p><strong>Background: </strong>The number of newly diagnosed cases of human immunodeficiency virus (HIV) infection in Korea, which had increased until 2019, has markedly decreased since the coronavirus disease 2019 pandemic started. This study evaluated whether the decrease is due to a reduction in the incidence of HIV infection and/or delayed diagnosis during the pandemic.</p><p><strong>Materials and methods: </strong>We reviewed the medical records of 587 newly diagnosed patients with HIV infection between February 2018 and January 2022 from four general hospitals, and their characteristics were compared between the pre-pandemic and pandemic periods. The lapse time from infection to diagnosis was estimated using an HIV modeling tool.</p><p><strong>Results: </strong>The estimated mean times to diagnosis were 5.68 years (95% confidence interval [CI]: 4.45 - 6.51 years) and 5.41 years (95% CI: 4.09 - 7.03 years) before and during the pandemic, respectively (<i>P</i> = 0.016). The proportion of patients with acquired immunodeficiency syndrome-defining illnesses, expected to visit hospitals regardless of the pandemic, decreased from 17.2% before the pandemic to 11.9% during the pandemic (<i>P</i> = 0.086).</p><p><strong>Conclusion: </strong>The decrease in the number of newly diagnosed cases of HIV infection in Korea might have resulted from an actual decrease in the incidence of HIV infection rather than a worsening of underdiagnosis or delayed diagnosis.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"451-459"},"PeriodicalIF":2.8,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10771950/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10542283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of Disease Burden and Immunization Rates for Vaccine-Preventable Diseases in People Living with HIV: The Korea HIV/AIDS Cohort Study.","authors":"Hye Seong, Yunsu Choi, Kyoung Hwan Ahn, Jun Yong Choi, Shin-Woo Kim, Sang Il Kim, Mee-Kyung Kee, Bo Youl Choi, Boyoung Park, Hak Jun Hyun, Jin Gu Yoon, Ji Yun Noh, Hee Jin Cheong, Woo Joo Kim, Joon Young Song","doi":"10.3947/ic.2023.0045","DOIUrl":"10.3947/ic.2023.0045","url":null,"abstract":"<p><strong>Background: </strong>Prophylactic immunization is important for human immunodeficiency virus (HIV)-infected patients; however, there are insufficient data on the burden of vaccine-preventable diseases (VPDs), vaccination rates, and factors influencing vaccination.</p><p><strong>Materials and methods: </strong>The incidence and prevalence of VPDs in HIV-infected patients between 2006 and 2017 were estimated using the Korean HIV/acquired immune deficiency syndrome (AIDS) cohort database. In addition, we evaluated the vaccination rates and influencing factors for vaccination in HIV-infected patients through multilevel analysis of clinico-epidemiological factors, immune status, and psychological status. A questionnaire survey was conducted among experts to determine whether they recommend vaccination for HIV-infected patients.</p><p><strong>Results: </strong>The incidence rates of hepatitis B virus (HBV) infection, herpes zoster, and anogenital warts were 1.74, 7.38, and 10.85 per 1,000 person-years, respectively. The prevalence of HBV infection and anogenital warts at enrollment was 4.8% and 8.6%, respectively, which increased to 5.3% and 12.0%, respectively, by 2017. In HIV-infected patients, HBV (21.7% in 2008, 56.3% in 2013, and 75.4% in 2017) and pneumococcal vaccination rates (3.0% in 2015, 7.6% in 2016, and 9.6% in 2017) increased annually, whereas the influenza vaccination rate remained similar by season (32.7 - 35.6%). In the multilevel analysis, peak HIV viral load (≥50 copies/mL: odds ratio [OR] = 0.64, 95% confidence interval [CI]: 0.44 - 0.93; reference, <50 copies/mL) was an influencing factor for pneumococcal vaccination, while nadir CD4 T-cell counts (200 - 350 cells/mm³: OR = 0.54, 95% CI: 0.38 - 0.76; <200 cells/mm³: OR = 0.89, 95% CI: 0.62 - 1.28; reference, ≥350 cells/mm³) was an influencing factor for HBV vaccination. Influenza vaccination was associated with male sex (OR = 1.94) and the number of antiretroviral therapy (ART) regimen change (OR = 1.16), but was not significantly associated with HIV viral load or CD4 T-cell counts. Most experts responded that they administer hepatitis A virus, HBV, pneumococcal, and influenza vaccines routinely, but not human papillomavirus (12.9%) or herpes zoster vaccines (27.1%).</p><p><strong>Conclusion: </strong>The burden of vaccine-preventable diseases was quite high in HIV-infected patients. Nadir CD4 T-cell counts, peak HIV viral loads, and the number of ART regimen change are significant factors related to vaccination. Considering the low vaccination rates for VPDs, there was a discordance between experts' opinions and real clinical practice in the medical field.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"441-450"},"PeriodicalIF":4.2,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10771952/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10169903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}